Matinas BioPharma
MTNB
25 hedge funds and large institutions have $166K invested in Matinas BioPharma in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
14% more funds holding
Funds holding: 22 → 25 (+3)
0.97% less ownership
Funds ownership: 7.26% → 6.29% (-0.97%)
14% less capital invested
Capital invested by funds: $194K → $166K (-$27.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$12.4K |
| 2 |
Renaissance Technologies
New York
|
+$2.49K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.94K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.07K |
| 5 |
CAM
Costello Asset Management
Feasterville,
Pennsylvania
|
+$118 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$27.7K |
| 2 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$13.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.32K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
-$1 |
MTNB Hedge Fund Activity: Q1 2025 in Review
25 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2025, worth a combined $166K — down 14% from $194K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MTNB positions and 2 closed out — a net gain of 3 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $12.4K. The largest seller was Vanguard Group, cutting an estimated $27.7K.
- 25 institutional investors held Matinas BioPharma (MTNB) as of Q1 2025, up from 22 in Q4 2024.
- Funds reported $166K of Matinas BioPharma stock for Q1 2025, down 14% quarter-over-quarter.
- 5 funds opened new Matinas BioPharma positions in Q1 2025 and 2 closed out, a net change of +3 holders.
- The largest Matinas BioPharma buyer in Q1 2025 was Two Sigma Securities, an estimated $12.4K added.
- The largest Matinas BioPharma seller in Q1 2025 was Vanguard Group, an estimated $27.7K sold.
Based on aggregated 13F filings for Q1 2025.